Search Bar & Filters
Found 67 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying the potential of EA-230, a new therapy, to help patients recover faster and experience fewer complications after Coronary Artery Bypass Grafting CABG surgery for Coronary Artery Disease CAD. This Phase III trial is designed to confirm earlier findings that EA-230 was safe and reduced hospital and ICU stays compared to a placebo. The study is randomized, double-blind, and placebo-controlled to ensure unbiased results. Participants will receive either EA-230 or a placebo intravenously at a dose of 90 mgkg per hour for 4 hours during surgery. The trial includes multiple visits a screening visit, a pre-operative visit, 7 hospital visits during the stay, and 2 remote visits, totaling 10 visits over about 71 days. The study compares hospital length of stay and other post-surgery recovery measures. During participation, patients will undergo various assessments including monitoring of hospital and ICU stay durations, hemodynamic stability, and blood plasma levels of EA-230 shortly after administration. Safety evaluations will also be conducted up to 28 days post-surgery. Overall, participants will be followed for approximately 71 days to capture recovery outcomes and safety data.
Actively Recruiting
Researchers are studying advanced non-small cell lung cancer NSCLC with a specific KRAS G12C gene mutation to see if adding the drug LY3537982 olomorasib to standard anti-cancer treatments provides better outcomes than standard treatment alone. This Phase 3 trial evaluates different combinations including pembrolizumab with or without chemotherapy. The study is sponsored by Eli Lilly and Company and aims to improve first-line treatment options for people with this type of lung cancer. Participants receive LY3537982 orally along with pembrolizumab intravenously in 21-day cycles. Some groups also receive chemotherapy drugs like pemetrexed and platinum agents cisplatin or carboplatin. There are various study parts including dose optimization, safety lead-in, and randomized treatment arms comparing LY3537982 combinations to placebo with pembrolizumab, with or without chemotherapy. Treatment continues until certain discontinuation criteria are met. During the study, participants will have regular visits for assessments including tumor measurements, physical function, symptom questionnaires, and safety monitoring. Researchers will measure progression-free survival, treatment side effects, response rates, and quality of life over an estimated period of up to three years depending on individual progress. Participants will be closely monitored throughout to evaluate the effects and safety of the study drug combinations.
Actively Recruiting
Researchers are evaluating GB-0895 as an additional therapy for adolescents and adults with severe asthma that remains uncontrolled despite treatment with inhaled corticosteroids and other standard asthma controllers. This global, multicenter, randomized, double-blind, placebo-controlled Phase 3 study aims to assess the efficacy and safety of GB-0895 in improving health outcomes for this population, with an optional open-label extension phase. Participants will receive subcutaneous injections of either GB-0895 or a placebo every six months over a 52-week treatment period. The study includes a screening and run-in phase lasting up to five weeks before treatment starts. After the treatment phase, participants will enter a follow-up period lasting from week 52 to week 90 or may opt to join an open-label extension lasting until week 142. During the study, participants will be regularly assessed for asthma exacerbations, lung function changes, quality of life, symptom control, and safety measures including lab tests, vital signs, and ECGs. Researchers will monitor the annualized asthma exacerbation rate as the primary outcome and evaluate additional respiratory and quality of life assessments. The total participation time may extend up to nearly three years for those in the optional open-label extension.
Actively Recruiting
Researchers are studying sepsis-induced coagulopathy, a serious condition where an infection causes an excessive immune response leading to harmful blood clots that damage blood vessels and organs. This phase 1 study aims to understand the safety, proper dosing, and effects of BAY 3389934 in patients treated in intensive care units for this condition. The goal is to evaluate adverse events and how participants respond to the drug. Participants will receive BAY 3389934 through a continuous intravenous infusion over up to 96 hours. They will be divided into two groups the first group receives a low starting dose with possible adjustments based on safety and tolerability. If there are no serious side effects, the second group receives a higher dose. This dose escalation approach helps find a suitable dose for patients with sepsis-induced coagulopathy. During the approximately 28-day study period, participants will have blood and urine samples taken, physical exams, and vital signs like body temperature, blood pressure, and heart rate monitored. Heart health will be assessed with an electrocardiogram ECG. Researchers will carefully record any medical problems that occur during and after treatment to track safety. The study monitors participants closely to understand the drugs effects and tolerability.
Actively Recruiting
Researchers are studying adults aged 45 to 80 who have high levels of Lipoproteina, known as Lpa, a protein linked to higher risk of heart disease. The trial aims to compare the effects of lepodisiran, a drug given by injection, to a placebo on the amount and type of plaque in the hearts vessels using advanced imaging called Coronary Computed Tomography Angiography CCTA. This study is a Phase 3 randomized, double-blind trial focusing on treatment for cardiovascular disease or risk for a first cardiovascular event. Participants will receive either lepodisiran or a placebo by subcutaneous injection. The study will follow them for about 120 weeks, including assessments at baseline and at Week 104 to measure changes in noncalcified plaque volume in the coronary arteries. Secondary measures include changes in fat attenuation index, Lpa levels, participant feedback on the injection experience, and drug pharmacokinetics. During the study, participants will undergo imaging scans, blood tests, and questionnaires at scheduled times to track the effects of the drug compared to placebo. Researchers will monitor the plaque in coronary arteries and Lpa levels to understand how lepodisiran may impact cardiovascular health. Safety and participant experience with the treatment will also be assessed throughout the trial duration.
Actively Recruiting
Researchers are studying a new treatment approach for older adults with acute myeloid leukemia AML who are not suitable for intensive chemotherapy. This Phase II trial focuses on using a combination of azacitidine and venetoclax, with the addition of cobicistat to potentially reduce the venetoclax dose and lower treatment costs. The study aims to optimize venetoclax dosing while maintaining treatment effectiveness and safety in this patient group. Participants will receive azacitidine and venetoclax from the first treatment cycle until disease relapse. Cobicistat is added from cycle 2 during the initial run-in phase for some patients and from cycle 1 during the extension phase. This sequential design allows assessment of how cobicistat affects venetoclax exposure and pharmacokinetics. The study is single-arm and evaluates this combination treatment over several cycles. During the trial, participants will be closely monitored through pharmacokinetic measurements comparing cycles with and without cobicistat. Researchers will assess overall survival and various remission rates using established leukemia response criteria. Safety will be evaluated by tracking adverse events, early mortality, and treatment adherence. Genetic studies and cost analyses are also part of the long-term follow-up, which may last up to four years after starting treatment.
Actively Recruiting
This research aims to evaluate whether preventive endovascular stenting of a significant narrowing over 50% in the superior mesenteric artery SMA can reduce the risk of anastomotic leakage AL after elective colon surgery. AL is a serious complication linked to higher mortality, lower quality of life, and increased healthcare costs. A prior study showed that having more than 50% SMA stenosis raises the risk of AL sixfold, and this trial investigates if stenting this artery before surgery can help prevent AL. Participants are randomly assigned to one of two groups the intervention group will receive preventive angioplasty and placement of a covered stent in the SMA before their colon surgery, while the control group will proceed with colon surgery without stenting. Both groups receive daily mono antiplatelet therapy with carbasalate calcium, lifelong for the intervention group and at least 12 months for the control group. The stenting procedure is minimally invasive and performed preferably within two weeks before surgery at specialized centers. Colon surgery is done according to standard local guidelines. Some centers will use intraoperative fluorescence angiography to assess blood flow during surgery. During the 12 months of follow-up after surgery, participants will be monitored for anastomotic leakage within the first 90 days, as well as delayed leakage and surgical complications up to one year. Researchers will collect data on hospital stays, reinterventions, mortality, quality of life, healthcare costs, and stent function. Patient-reported outcomes will be gathered through questionnaires at multiple time points. The study also includes imaging assessments and cost-effectiveness analyses to understand the broader impact of preventive stenting.
Actively Recruiting
Researchers are evaluating a shorter treatment duration with androgen receptor pathway inhibitors ARPIs, specifically Apalutamide or Enzalutamide, in patients with low-volume hormone-sensitive metastatic prostate cancer. This phase 3 clinical trial aims to determine if stopping ARPI therapy after 12 months, with the option to restart if the cancer progresses, is not worse than continuing ARPI treatment. The goal is to reduce side effects and costs while maintaining effective disease control. Participants will be randomly assigned after completing 12 months of ARPI treatment to one of two groups one group will continue androgen deprivation therapy ADT combined with ARPI, while the other will stop ARPI after 12 months but may restart it if a confirmed rise in prostate-specific antigen PSA occurs. The PSA confirmation sample must be taken at least four weeks after the initial rise. Treatment will be monitored closely according to these protocols. During the study, participants will be followed for up to 6 years, including 5 years after randomization to track clinical progression-free survival. Researchers will regularly assess disease status, treatment effects, and possible side effects. The study includes regular visits and monitoring to evaluate how long patients remain free from disease progression while comparing the two treatment approaches.
Actively Recruiting
Researchers are studying how using a supportive soft-robotic glove affects real arm and hand use during daily life for people with hand function limitations caused by trauma-related injuries or neurological conditions. This study follows up on earlier research with previous versions of the robotic glove Carbonhand to better understand its therapeutic effects. The study involves 3 to 5 participants and uses a single-case experimental design to observe changes over time. Participants will use the Carbonhand soft-robotic glove at home for six weeks during daily activities that are important to them, supporting the grip of their most affected hand. They can choose which activities and when to use the glove but are encouraged to use it at least 180 minutes per week. The study includes three phases a baseline phase without the glove, the intervention phase using the glove, and a retention phase without the glove again. Throughout the 12 to 14 weeks of the study, participants will complete about 15 home assessments spread across the three phases. These assessments include wearing activity meters on both wrists during waking hours, performing hand grip strength tests via video calls, and answering questions on hand function and well-being. Additional evaluations involve questionnaires, hand function tests, pain ratings, and interviews. The glove also collects usage data and participants keep a diary during the intervention phase. This thorough monitoring helps researchers measure actual arm activity and other outcomes related to hand use and quality of life.
Actively Recruiting
Researchers are investigating the best approach to treat low-risk patients with isolated subsegmental pulmonary embolism SSPE, a type of blood clot in small lung arteries. The study aims to determine whether monitoring patients without anticoagulation is as safe and effective as giving anticoagulant medication. This is important because many patients currently receive anticoagulants that carry a risk of bleeding, but it is unclear if all patients with isolated SSPE need this treatment. Patients in the trial are randomly assigned to one of two groups. One group receives the anticoagulant drug rivaroxaban, starting with 15 mg twice daily for 21 days, then 20 mg once daily for a total of 90 days. The other group receives a placebo matching the same schedule. The trial compares clinical surveillance without anticoagulation to anticoagulation treatment to assess safety and effectiveness. Participants will be followed for 90 days after randomization to monitor for recurrent venous thromboembolism, significant bleeding events, and overall survival. Researchers will track these outcomes through clinical assessments and safety monitoring. This study is designed to evaluate if careful monitoring alone is a safe alternative to anticoagulation in selected patients with isolated SSPE, potentially reducing bleeding risks from treatment.
1-10 of 67
1